Literature DB >> 1457211

Analysis of HIV-1 envelope mutants and pseudotyping of replication-defective HIV-1 vectors by genetic complementation.

E L Delwart1, G L Buchschacher, E O Freed, A T Panganiban.   

Abstract

Infectious HIV-1 particles containing replication-defective vectors that express the hygromycin B phosphotransferase gene were generated by transient complementation in COS-1 cells. A defective vector dependent only on trans-complementation with an env gene and a small vector containing a deletion of almost all of the trans region were used to examine pseudotyping of HIV-1 by an amphotropic murine retrovirus. Although pseudotyping by the heterologous envelope glycoprotein occurred with efficiency, no pseudotyping at the RNA level was observed. Genetic complementation was used to rapidly analyze the effect of env mutations in the V3, proteolytic processing site, fusion domain, and cytoplasmic tail on viral infectivity. Mutations decreasing syncytium formation usually also lowered infectivity. However, a mutation in the cytoplasmic tail and a separate mutation adjacent to the fusion domain dramatically decreased viral particle infectivity but did not appreciably decrease envelope glycoprotein-mediated cell-to-cell fusion. These results may indicate that these regions of the transmembrane peptide are necessary for acquisition of envelope glycoprotein by budding virus particles or for virus entry.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457211     DOI: 10.1089/aid.1992.8.1669

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

2.  Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

Authors:  L D Giavedoni; T Yilma
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR.

Authors:  M T Dittmar; G Simmons; Y Donaldson; P Simmonds; P R Clapham; T F Schulz; R A Weiss
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures.

Authors:  M S McBride; A T Panganiban
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles.

Authors:  T A Rizvi; A T Panganiban
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

6.  Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor.

Authors:  J He; N R Landau
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant.

Authors:  G L Buchschacher; E O Freed; A T Panganiban
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.

Authors:  E O Freed; M A Martin
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function.

Authors:  R J Geraghty; A T Panganiban
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  A double hairpin structure is necessary for the efficient encapsidation of spleen necrosis virus retroviral RNA.

Authors:  S Yang; H M Temin
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.